High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. Here's why these two high-yield ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

A drug projected to have over $3B peak sales potential, Oxbryta was added to Pfizer's (PFE) portfolio following its $5B acquisition of Global Blood Therapeutics in 2022. "For large pharma ...

Pfizer, Inc. and Global Blood Therapeutics, Inc. were sued in San Francisco Superior Court where the plaintiff alleges the drug Oxbryta contributed to the onset of a vaso-occlusive crisis (VOC) as ...

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ...

and pulling its sickle cell disease treatment Oxbryta due to deaths in clinical trials. Pfizer declined to comment for the story. Gabelli's Jonas said he would like Pfizer to tighten its focus on ...

FILE PHOTO: Jeffrey Smith, Managing Member, CEO and CIO of Starboard Value, speaks during the 13D Monitor's Active-Passive Investor Summit in New York City, U.S., October 18, 2022. REUTERS/Brendan ...

This growth guidance considers the reduction of sales associated with the previously announced global withdrawal of Oxbryta. Pfizer Expects 2024 adjusted EPS of $2.75-$2.95 compared to prior ...